Welireg, Padcev, and a surprise fillip for Flare.
ApexOnco Front Page
Recent articles
Two new pivotal Chinese first-line trials have started in lung cancer.
Readout of the delayed Galaxies Lung-201 study is due imminently.
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.